Kiniksa(US:KNSA)2023-11-02 08:08Financial Performance - ARCALYST net product revenue is expected to be $220-$230 million in 2023, representing approximately 84% growth at the midpoint[7, 25] - Q3 2023 ARCALYST net sales reached $64.8 million, a ~94% year-over-year growth compared to $33.4 million in Q3 2022[9, 32, 46] - The company's cash, cash equivalents, and short-term investments amounted to $201.1 million as of September 30, 2023[7, 31] - The company anticipates its cash reserves will fund the current operating plan into at least 2027[7, 47] ARCALYST Commercial Execution - ARCALYST has achieved >1,450 total prescribers[9] - Repeat prescribers account for approximately 24% of the total prescribers[9] - Payer approval rate for ARCALYST is >90% of completed cases[9] - Patient compliance with ARCALYST therapy is >85%[9] - Only 5% penetration of target recurrent pericarditis population as of YE22[7] KPL-404 Program - KPL-404 is currently in a Phase 2 study and is considered a potentially best-in-class asset[7]